Signati Submits De Novo Application to FDA After Completing Trial

Signati has reached a pivotal milestone by submitting a De Novo application to the U.S. Food and Drug Administration (FDA) after the successful completion of its trial. This submission is a crucial step in the regulatory pathway for new medical devices that are of a type not previously classified by the FDA. The De Novo process provides a pathway to classify novel devices of low to moderate risk that have been determined to be safe and effective for their intended use, but for which there is no legally marketed predicate device. This move by Signati signifies a significant advancement in bringing innovative medical technologies to the market, ensuring they meet the stringent safety and efficacy standards set by the FDA.